SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-21-000025
Filing Date
2021-05-06
Accepted
2021-05-06 16:30:31
Documents
41
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ctic-20210331.htm   iXBRL 10-Q 682245
2 EX-10.1 ex101ctibiopharmacorpdirec.htm EX-10.1 19564
3 EX-31.1 ex311-ceo302q1fy21.htm EX-31.1 11325
4 EX-31.2 ex312-cfo302q1fy21.htm EX-31.2 12193
5 EX-32 ex32-ceocfo906q1fy21.htm EX-32 11629
  Complete submission text file 0000891293-21-000025.txt   2998896

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20210331.xsd EX-101.SCH 20323
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20210331_cal.xml EX-101.CAL 50807
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20210331_def.xml EX-101.DEF 125183
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20210331_lab.xml EX-101.LAB 282506
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20210331_pre.xml EX-101.PRE 176682
11 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20210331_htm.xml XML 356020
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 21898317
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences